BIOCRYST PHARMACEUTICALS, INC. (BCRX) Free cash flow 2016–2025
BIOCRYST PHARMACEUTICALS, INC. (BCRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$344.9MFY2025 · since FY2016: -$58.7M → $344.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $344.9M | +749.0% |
| FY2024 | -$53.1M | +45.4% |
| FY2023 | -$97.3M | +40.4% |
| FY2022 | -$163.2M | -12.9% |
| FY2021 | -$144.5M | -6.6% |
| FY2020 | -$135.6M | -50.8% |
| FY2019 | -$89.9M | +3.2% |
| FY2018 | -$92.9M | -124.1% |
| FY2017 | -$41.5M | +29.4% |
| FY2016 | -$58.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More BCRX financial trends
BCRX RevenueBCRX Net incomeBCRX Net marginBCRX Gross profitBCRX Gross marginBCRX Operating incomeBCRX Operating marginBCRX Operating cash flowBCRX Capital expendituresBCRX Return on equityBCRX Stock buybacksBCRX Dividends paidBCRX Total assetsBCRX Total liabilitiesBCRX Shareholders’ equityBCRX overview →